Ichiro et al. have reported that dual inhibition of MET and RON signaling pathways by small-molecule inhibitor LY2801653 achieved dramatic antitumor effects in non-small cell lung cancer [36]. Here, MST1R is linked to non-small cell lung carcinoma.